Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Sleep Problems in Alzheimer's Disease
NCT00000171Phase 3Completed
- Sponsor
- National Institute on Aging
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of melatonin in dyssomnia (3 arms), sponsored by National Institute on Aging. Primary endpoint: Change in nocturnal sleep time at 8 weeks. Status: completed.
02
Drugs
melatonin
03
Conditions
dyssomnia
Beyond the preview
Go deeper on NCT00000171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000171.